Q-omics provides the consensus-scored TMEM141 profile across patient tissues and cancer cell-line models. TMEM141 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM141 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, TMEM141 RNA expression shows 18,769 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, LIHC, and DLBC as cancer lineages where TMEM141 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM141 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM141 survival associations across molecular data types. TMEM141 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM141 RNA expression–survival associations across cancer types. High TMEM141 expression shows unfavorable associations in ACC, BLCA, HNSC, LIHC, UVM and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM141 RNA expression.
This table summarizes TMEM141 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM141. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM141 shows lower tumor expression in KIRC and higher tumor expression in LIHC, BRCA, CHOL, BLCA and PAAD. The LIHC box plot shows higher TMEM141 RNA expression in tumor versus normal tissue (log2 FC = +0.904, t-test p < 0.001).
This table shows molecular features associated with TMEM141 in patient tissues and cancer cell lines. In patient samples, TMEM141 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM141 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
